SEVER’s Core Strength
The core strength of SEVER Life Sciences lies in the range of what our companies offer to patients across the world. Created as a holding company in 2019, SEVER brings together four diverse but complementary companies, each with their own expertise and specialist focus. As a result, SEVER oversees an unrivalled and uniquely successful range of products, services and technologies.
The four companies – Amring USA, Izvarino, Nordic Pharma and Pharma Services – are all united by a common purpose: a concern for patients. These companies provide new drugs for unmet medical needs; they supply consistent, relevant and high-quality generic drugs; and they develop, license and manufacture pharmaceutical products.
SEVER Life Sciences has therefore been created to fully exploit this diversity and to significantly increase overall value and benefits for customers, shareholders and – above all – patients.
Chief Executive Officer
The Sever executive team is constituted of a group of seasoned managers with relevant experience in their respective domains and markets
Chief Executive Officer
Sean has over 30 years of experience in the pharmaceutical industry. He started his career in sales and market research roles with A H Robins and progressed…
CEO, Amring USA
President and CEO of Amring Pharmaceuticals Inc. in USA with 5+ years building Amring from startup in the USA and a total of 19 years in the pharmaceutical industry. Daniel was graduated with a Bachelors degree in chemical engineering from Princeton University, with an MBA from Rutgers University in New Jersey, and from the Officers Basic Course in the U.S. Army Field Artillery School in Oklahoma. He has 38 years of experience starting, restructuring, acquiring and improving businesses in the pharmaceutical, consumer health, food and consumer products, environmental management, and strategic consulting fields. Daniel has progressed through large, small, and turnaround companies including Endo Pharmaceuticals, Procter and Gamble, Nabisco, KPMG, SmithKline Beecham, Axcentria, and the US Army.
CEO, Pharma Services
CEO of Pharmaceutical Services group at Sever Life Sciences, Kenneth brings 25 years of pharmaceutical industry experience. Kenneth joined QPharma as CEO in 2009 and has served in several roles at Nordic Group, including SVP of Technical operations and Strategic Development. Prior to this, he spent eight years in several international positions with Xellia pharmaceuticals, incl GM China, and five years in different technical roles with Novo Nordisk. Kenneth holds an MSc in chemical engineering from the technical university of Denmark (DTU) and an executive MBA from HEC in Paris.
CEO, Izvarino Pharma
General manager of Izvarino Pharma LLC from 2010 to the present. General manager of Nanopharma Development from 2016 to the present. In the Russian pharmaceutical business since 1996. Present activities together with the Russian team introduced to the Russian market the company Astellas Pharma and carried out the development of the Russian company Alium. Medical Doctor, pharmacologist (PhD), DBA (Higher School of Economics, Moscow), Stanford graduate school of business (Stanford, CA).
Aernout de Bruijne
Director of Finance & Operations Planning
Director of Finance & Operating Planning working in the pharmaceutical industry over nine years and prior to this held several international positions in the software industry, over a ten year period for Informatica, a US public IT company taken private, as well as the private IT company Information Builders, overseeing international finance functions within Europe and Australia. Holding a bachelor degree in business economics and a MBA from NCOI.